228869-36-1

Basic information

• Product Name: 3-benzyloxy-N,N-diethyl-4-methoxy-benzamide
• Synonyms: 3-benzyloxy-N,N-diethyl-4-methoxy-benzamide
• CAS NO: 228869-36-1
• Molecular Weight: 313.397
• Mol File: 228869-36-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 3-benzyloxy-N,N-diethyl-4-methoxy-benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-benzyloxy-N,N-diethyl-4-methoxy-benzamide(228869-36-1)
• EPA Substance Registry System: 3-benzyloxy-N,N-diethyl-4-methoxy-benzamide(228869-36-1)

Safety Data

• Hazardous Substances Data: 228869-36-1(Hazardous Substances Data)

Upstream product

• 6346-05-0 3-benzyloxy-4-methoxybenzaldehyde 
• 58452-00-9 3-benzyloxy-4-methoxybenzoic acid 
• 41222-60-0 3-benzyloxy-4-methoxybenzoyl chloride 
• 109-89-7 diethylamine 

Downstream Products

• 228869-37-2 3-Benzyloxy-N,N-diethyl-2-formyl-4-methoxy-benzamide 
• 256443-15-9 1-(3,5-dichloro-pyridin-4-ylmethyl)-6-methoxy-5-(5-phenyl-pent-1-ynyl)-phthalazine 
• 228869-42-9 6-methoxy-5-(5-phenyl-pentyloxy)-2H-phthalazin-1-one 
• 256443-86-4 6-methoxy-5-(5-phenyl-pent-1-ynyl)-2H-phthalazin-1-one 
• 256443-87-5 1-Chloro-6-methoxy-5-(5-phenyl-pent-1-ynyl)-phthalazine 

Relevant articles and documents

The synthesis and biological evaluation of a novel series of phthalazine PDE4 inhibitors I

This communication describes the synthesis and in vitro evaluation of a novel and potent series of phosphodiesterase type IV (PDE4) inhibitors. The compounds described represent conformationally constrained analogues of RP 73401, Piclamilast. Preliminary evidences of reduced side effects of 11 compared to standards are also reported. (C) 2000 Elsevier Science Ltd.

Phthalazine derivatives as phosphodiesterase 4 inhibitors

The present invention provides a compound selected from the group including: N-3-acetyl-1-(3,5-dichloropyridin-4-ylmethyl)-5-cyclopentyloxy-6-methoxy-4H-phthalazine; 6,7-dimethoxy-1-pyridin-4-ylmethyl-4-thiazol-2-yl-phthalazine; 1-(6,7-dimethoxy-4-pyridin-4-ylmethyl-1H-phthalazin-2-yl)ethanone; 2-methanesulphonyl-6,7-dimethoxy-4-pyridin-4-ylmethyl-1,2-dihydrophthalazine; 2-formyl-6,7-dimethoxy-4-pyridin-4-ylmethyl-1,2-dihydrophthalazine; 1-(6,7-dimethoxy-4-pyridin-4-ylmethyl-1H-phthalazin-2-yl)-1-imidazol-1-ylmethanone; 1-(3,5-dichloro-pyridin-4-ylmethyl)-3-methansulphonyl-6-difluoromethoxy-5-(tetrahydro-furan-2-yloxy)-4H-phthalazine; N→O derivatives thereof; and pharmaceutically acceptable salts thereof. The invention also provides a pharmaceutical composition, which contains a therapeutically effective amount of the above compound in admixture with a pharmaceutically acceptable carrier.